Research
Hormonal
Semaglutide improves cardiometabolic risk factors, including diastolic blood pressure, in patients without diabetes, while maintaining renal stability in both diabetic and non-diabetic populations.
Semaglutide offers cardiovascular benefits beyond weight loss, such as lowering diastolic blood pressure in non-diabetics. It also appears to protect kidney function (stable creatinine and albumin/creatinine ratio) in both diabetic and non-diabetic patients, making it a favorable option for those with cardiometabolic risks.
ModerateSupportsMEDIUM confidence
Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio.
Why this rating
Retrospective observational study, no control group.
Source
Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia
Muhammad Imran Butt et al. · Annals of Saudi Medicine · 2024
DOI 10.5144/0256-4947.2024.361
cohort · n=1007Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly subcutaneous semaglutide (1 mg) produces clinically significant weight loss (median 4.4% in diabetics, 3.4% in non-diabetics) and improves glycemic control (HbA1c reduction of 0.4%) in patients with type 2 diabetes over 6 months.Moderate
- Semaglutide (1 mg) promotes significant weight loss and improves BMI in patients without Type 2 Diabetes, without causing significant changes in HbA1c or hypoglycemia risk.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →